Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 11, 2013, Pages 963-967

  Rabi, Doreen M ^a   Padwal, Raj ^b   Tobe, Sheldon W ^c   Gilbert, Richard E ^d   Leiter, Lawrence A ^e   Quinn, Robert R ^f   Khan, Nadia ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; FAINTNESS; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

EID: 84881522762     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.120112     Document Type: Review

References (17)

1. Report from the Canadian Chronic Disease Surveillance System: hypertension in Canada, 2010. Ottawa (ON): Chronic Disease Surveillance Division, Centre for Chronic Disease Prevention and Control; 2010.
2. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.
3. Turnbull F, Neal B, Algert C, et al. Effects of different bloodpressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
5. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2013;36:S1-110.
6. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-58.
7. Daskalopoulou SS, Khan N, Quinn RR, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk and therapy. Can J Cardiol 2012; 28: 270-87.
8. Khan NA, McAlister FA, Campbell NRC, et al. The 2004 Canadian recommendations for the management of hypertension: Part II-therapy. Can J Cardiol 2004;20:41-54.
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
10. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-97.
11. McAlister FA. The Canadian Hypertension Education Program-a unique Canadian initiative. Can J Cardiol 2006;22:559-64.
12. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
13. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
14. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects metaanalyses of randomized trials. Circulation 2011;123:2799-810.
15. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011;29: 1253-69.
16. McAlister FA, Straus SE, Sackett DL, et al. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289: 2545-53.
17. Rabi DM, Daskalopoulou SS, Padwal RS, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011; 27: 415-33.